Topic:

M&A

Latest Headlines

Latest Headlines

Incoming Takeda chief ready to jump on the M&A train with reorg in place

Step one for incoming Takeda CEO Christophe Weber: Reorganize. Step two? Scout deals, he said Wednesday.

Actavis CEO: Pharma believer and Botox user, yes. The Borg? No

Actavis CEO Brent Saunders is committed to his company, its employees and the brands it sells--at least, that's the image he projected when he received Botox, the lead product from recent purchase Allergan, on a stage in front of 1,000 of the California drugmaker's sales reps.

India opens medical device industry to foreign direct investment

India's medical device industry will officially open Jan. 21 to unlimited foreign direct investment as the government kicks off what is expected to be a year of vast changes in the way it regulates the products.

Actavis working to add Allergan CEO Pyott to board: Reuters

Back in November, Actavis said it would invite two members of Allergan's board to join the ranks of the new company's directors in the wake of their $66 billion merger. And according to Reuters ' sources, Allergan CEO David Pyott is one of them.

Glaxo CEO: Consumer health IPO may be in our future

When GlaxoSmithKline's multibillion-dollar asset swap with Novartis closes this year, don't expect the British pharma giant to stop there, its CEO says--especially when it comes to consumer health.

Depomed picks up U.S. Nucynta rights as J&J's cast-off moves continue

Earlier this week, once-skeptical Johnson & Johnson CEO Alex Gorsky seemed to be fully on-board pharma's slim-down bandwagon, telling presentation-watchers at the JP Morgan Healthcare Conference he was willing to jettison pieces of the J&J puzzle if they didn't present a "path to achieving leadership." Now, he's followed up with another divestment that will send U.S. rights to pain med Nucynta to California's Depomed.

Medical device, diagnostic venture investment at $2.7B, highest since 2008

Med tech venture investing may lag biotech by more than half, but it's coming on strong. As venture-backed exits pick up, a real devotion to breakthrough innovation seems to be whetting investor appetites. A total of $2.7 billion was invested by VCs last year in medical devices and diagnostics, with $748 million of that total coming during the fourth quarter.

Roche bets $545M on Trophos' once-failed orphan drug

Roche has signed a deal to trade up to €470 million ($545 million) for Trophos, a company at work on a mid-stage treatment for the rare and debilitating spinal muscular atrophy.

With Rytary approval in the bag, Impax Labs scouts buyouts in CNS, generics

Sounds like Impax Laboratories' October pickup of Lineage Therapeutics and Tower Holdings was just the beginning of an M&A streak. The company is "aggressively hunting" further buyouts and is in ongoing talks with multiple targets, its CEO says.

The 2015 biotech takeover target list includes some hot new players

With the big multinationals like Merck, Roche, Pfizer and J&J joining some of the most aggressive biotechs (think Shire) in roaming the planet in search of the right biotech targets to acquire, you can expect to see a steady stream of fresh speculation among analysts over which companies figure as the most likely buyout--and the next place to score some quick cash by investors.